The Technical Analyst
Matinas BioPharma [MTNB]
Exchange: AMEX Industry: Biotechnology
Matinas BioPharma Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.63% $0.183
America/New_York / 23 apr 2024 @ 13:18
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 45.87 mill |
| EPS: | -0.110 |
| P/E: | -1.660 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 250.82 mill |
| Avg Daily Volume: | 1.565 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.660 | sector: PE 12.30 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -1.660 | industry: PE -5.55 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0992 (-154.23%) $-0.282 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.137 - 0.229 ( +/- 25.15%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-15 | Matkovits Theresa | Buy | 1 300 000 | Stock Option (right to Buy) |
| 2023-12-15 | Hoover Thomas | Buy | 1 000 000 | Stock Option (right to Buy) |
| 2023-12-15 | Kucinski Keith A | Buy | 1 000 000 | Stock Option (right to Buy) |
| 2023-12-15 | Liu Hui | Buy | 1 000 000 | Stock Option (right to Buy) |
| 2023-12-15 | Jabbour Jerome D | Buy | 3 500 000 | Stock Option (right to Buy) |
| INSIDER POWER |
|---|
| 97.56 |
| Last 97 transactions |
| Buy: 33 257 124 | Sell: 4 123 116 |
Forecast:
15:00 - $0.182
Live Trading Signals (every 1 min)
Forecast
1: 13:30 - $0.181
Forecast 2: 14:20 - $0.182
Forecast 3: 15:00 - $0.182
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.183 (1.63% ) |
| Volume | 0.414 mill |
| Avg. Vol. | 1.565 mill |
| % of Avg. Vol | 26.46 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MTNB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MTNB
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Latest Press Releases
2024-04-03 08:30:00 - Press Release
Matinas Biopharma Prices $10 Million Registered Direct Offering
Bedminster, n.j., april 03, 2024 (globe newswire) -- matinas biopharma holdings, inc. (nyse american: mtnb) (“matinas biopharma” or the “company”), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (lnc) platform delivery technology, today announced it has entered into securities purchase agreements with healthcare-focused institutional investors for the purchase and sale of 33,333,334 shares of common stock, par value $0.0001 per share, and warrants to purchase up to an aggregate of 33,333,334 shares of common stock, at a combined offering price of $0.30 per share and accompanying warrant, pursuant to a registered direct offering...
2024-03-27 16:05:00 - Press Release
Matinas Biopharma Reports 2023 Financial Results And Provides A Business Update
Clear registration pathway and fda agreement on the oralto phase 3 trial for mat2203 represent critical steps forward and supports partnership discussions
2024-03-25 08:00:00 - Press Release
Matinas Biopharma Announces Positive In Vivo Safety Data With Its Oral Lnc-docetaxel Formulation
Daily oral lnc-docetaxel, at a total administered dose of more than 8x greater than iv-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with iv-docetaxel
2024-03-22 09:15:00 - Press Release
Three Patients With Invasive Fusarium Infection In Matinas Biopharma's Oral Mat2203 Compassionate/expanded Use Access Program Achieve Complete Clinical Response
Bedminster, n.j., march 22, 2024 (globe newswire) -- matinas biopharma holdings, inc. (nyse american: mtnb), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (lnc) platform delivery technology, announces complete clinical response in three patients with serious invasive fusarium infection following treatment with mat2203, matinas' oral formulation of the potent antifungal amphotericin b. all three patients were enrolled in the company's compassionate/expanded use access program and were treated by marisa h. miceli, md, professor of medicine, specializing in fungal infections and transplant diseases, division of infectious diseases, internal medicine, at the university of michigan.
2024-03-22 06:30:00 - Press Release
Matinas Biopharma Regains Compliance With Nyse American Continued Listing Standards
Bedminster, n.j., march 22, 2024 (globe newswire) -- matinas biopharma holdings, inc. (nyse american: mtnb), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (lnc) platform delivery technology, today announced that on march 21, 2024, the company received written notification from the nyse american llc ("nyse american") stating that the company has regained compliance with the nyse american's continued listing standards. specifically, the company has resolved the continued listing deficiency with respect to the low selling price of its common stock as described in section 1003(f)(v) of the nyse american company guide due to shares of its common stock demonstrating sustained price improvement.
Latest News
2024-03-28 23:20:23 - Seeking Alpha
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript
2023-11-08 22:44:10 - Seeking Alpha
Matinas BioPharma Holdings, Inc. (MTNB) Q3 2023 Earnings Call Transcript
Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jody Cain - LHA IR Jerry Jabbour - CEO Terri Matkovits - CDO Terry Ferguson - CMO Keith Kucinski - CFO Conference Call Participants Julian Harrison - BTIG Operator Welcome to the Matinas BioPharma Third Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
2023-11-07 09:26:29 - PennyStocks
Penny Stocks To Buy Now? 3 to Watch With Big News
Let's talk penny stocks, those under-five-dollar shares that buzz with potential. They're nimble, sensitive to the slightest news, and can pivot on a dime.
2023-10-12 11:26:53 - Invezz
Top trending biotech stocks: ANVS, MTNB, AVTX, TPST
Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of the most notable M&A events this year were Pfizer's acquisition of Seagen, Eli Lilly's buyout of POINT Biopharma and Versanis Bio, and Roche's purchase of Good Therapeutics.
2023-09-28 07:00:00 - GlobeNewsWire
Matinas BioPharma to Present at Two Investment Conferences in October 2023
BEDMINSTER, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (LNC) platform technology, announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview and hold meetings with institutional investors at two upcoming investment conferences:
2023-09-06 07:00:00 - GlobeNewsWire
Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference
BEDMINSTER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that Jerome D. Jabbour, Chief Executive Officer, will hold meetings with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.
2023-07-26 08:00:00 - GlobeNewsWire
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023
BEDMINSTER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report second quarter 2023 financial results after market close on Wednesday, August 9, 2023. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
2023-05-11 07:30:00 - GlobeNewsWire
Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023
BEDMINSTER, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 9:30 a.m. Eastern time. The conference is being held at the New York Hilton Midtown.
2023-05-10 18:59:52 - Zacks Investment Research
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates
Matinas Biopharma Holdings, Inc. (MTNB) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.
2023-05-03 07:00:00 - GlobeNewsWire
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023
BEDMINSTER, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).